EGFR and non-small cell lung carcinoma: In 2015, gefitinib was FDA approved as a first line treatment in patients with metastatic NSCLC who harbor the most common types of EGFR mutations in NSCLC (exon 19 deletions or exon 21 L858R substitution gene mutations)40.